These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 29854003)

  • 21. [Antisense therapies for neurological diseases].
    Pulst SM
    Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy.
    Sheikh O; Yokota T
    BioDrugs; 2021 Jul; 35(4):389-399. PubMed ID: 34097287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy.
    Iftikhar M; Frey J; Shohan MJ; Malek S; Mousa SA
    Pharmacol Ther; 2021 Apr; 220():107719. PubMed ID: 33130193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translating Antisense Technology into a Treatment for Huntington's Disease.
    Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
    Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
    Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
    Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oligonucleotide therapeutics in neurodegenerative diseases.
    Scoles DR; Pulst SM
    RNA Biol; 2018; 15(6):707-714. PubMed ID: 29560813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense oligonucleotides: A primer.
    Scoles DR; Minikel EV; Pulst SM
    Neurol Genet; 2019 Apr; 5(2):e323. PubMed ID: 31119194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Better living through peptide-conjugated chemistry: next-generation antisense oligonucleotides.
    McNally EM; Leverson BD
    J Clin Invest; 2019 Nov; 129(11):4570-4571. PubMed ID: 31566581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey.
    Oberemok VV; Laikova KV; Repetskaya AI; Kenyo IM; Gorlov MV; Kasich IN; Krasnodubets AM; Gal'chinsky NV; Fomochkina II; Zaitsev AS; Bekirova VV; Seidosmanova EE; Dydik KI; Meshcheryakova AO; Nazarov SA; Smagliy NN; Chelengerova EL; Kulanova AA; Deri K; Subbotkin MV; Useinov RZ; Shumskykh MN; Kubyshkin AV
    Molecules; 2018 May; 23(6):. PubMed ID: 29844255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisense oligonucleotides: the next frontier for treatment of neurological disorders.
    Rinaldi C; Wood MJA
    Nat Rev Neurol; 2018 Jan; 14(1):9-21. PubMed ID: 29192260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders.
    Hill SF; Meisler MH
    Dev Neurosci; 2021; 43(3-4):247-252. PubMed ID: 34412058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.
    Rodrigues M; Yokota T
    Methods Mol Biol; 2018; 1828():31-55. PubMed ID: 30171533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antisense oligonucleotides: treating neurodegeneration at the level of RNA.
    DeVos SL; Miller TM
    Neurotherapeutics; 2013 Jul; 10(3):486-97. PubMed ID: 23686823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nusinersen in the Treatment of Spinal Muscular Atrophy.
    Goodkey K; Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
    Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
    Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exon-Skipping for a Pathogenic COL6A1 Variant in Ullrich Congenital Muscular Dystrophy.
    Aguti S; Guirguis F; Bönnemann C; Muntoni F; Bolduc V; Zhou H
    Methods Mol Biol; 2023; 2587():387-407. PubMed ID: 36401040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases.
    Verma A
    Ann Indian Acad Neurol; 2018; 21(1):3-8. PubMed ID: 29720791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies.
    Chamakioti M; Karantzelis N; Taraviras S
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Vitro Evaluation of Antisense-Mediated Exon Inclusion for Spinal Muscular Atrophy.
    Touznik A; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():439-454. PubMed ID: 30171558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.